CNS Pharmaceuticals (CNSP)
(Delayed Data from NSDQ)
$0.21 USD
0.00 (-1.72%)
Updated Apr 30, 2024 03:58 PM ET
After-Market: $0.21 0.00 (-0.62%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for CNS Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 19 | 15 | 14 | 9 | 4 |
Income After Depreciation & Amortization | -19 | -15 | -14 | -9 | -4 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -19 | -15 | -14 | -9 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | -15 | -14 | -9 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -19 | -15 | -14 | -9 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | -15 | -14 | -9 | -4 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -19 | -15 | -14 | -9 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.77 | 1.36 | 8.78 | 5.54 | 4.55 |
Diluted EPS Before Non-Recurring Items | -5.00 | -11.22 | -1.59 | -1.71 | -0.84 |
Diluted Net EPS (GAAP) | -5.00 | -11.22 | -1.59 | -1.71 | -0.84 |
Fiscal Year end for CNS Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.38 | 4.53 | 4.03 | 4.93 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.38 | -4.53 | -4.03 | -4.93 |
Non-Operating Income | NA | 0.01 | 0.01 | 0.01 | 0.00 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.01 |
Pretax Income | NA | -5.38 | -4.52 | -4.02 | -4.93 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.38 | -4.52 | -4.02 | -4.93 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.38 | -4.52 | -4.02 | -4.93 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 5.66 | 4.18 | 3.88 | 1.91 |
Diluted EPS Before Non-Recurring Items | NA | -0.95 | -1.08 | -1.04 | -2.59 |
Diluted Net EPS (GAAP) | NA | -0.29 | -1.08 | -1.04 | -2.59 |